Evotec SE (EVT) Earnings Call Transcripts

Evotec SE's Latest Earnings Call - Q4 FY2025

Evotec SE reported its fourth quarter and full year 2025 financial results, highlighting significant strategic shifts and operational improvements. For Q4 2025, revenues increased by 14.5% to EUR 253.3 million, while full-year revenues slightly declined by 1.1% to EUR 788.4 million, primarily due to challenges in the early-stage drug discovery market. The company achieved EUR 60 million in cost savings and reduced capital expenditure by 60%, strengthening its financial position. Management provided guidance for 2026, projecting revenues between EUR 700 million and EUR 780 million, with expectations of a market recovery and strategic partnership contributions in the second half of the year.

Reported metrics

Guidance from management

For 2026, Evotec guides group revenues between EUR 700 million and EUR 780 million, with adjusted EBITDA expected to be between EUR 0 million and EUR 40 million. Management anticipates a stronger second half due to market recovery and strategic partnerships.

What management said

So yes, you're correct, non-DOW non-Sandoz revenue growing 40%. We would expect to see that by the end of '26 that the non-Sandoz non-DoW revenue is about 50% of the overall Just business at this point in time. And that is a significant growth since 2024 when we were approximately 25%. And I believe in 2025, we're approximately 30%, to give you a little bit of a frame.

And I will hand over the third question to Cord, although Christian manage a bit the expectations typically, it should not be us talking about the intentions of the clinical assets of BMS, but maybe Cord can shed some light on that. On the second topic, the whole program was always constructed in a way that at some point in time, there will be an increasing amount of milestones and ultimately also royalty payments ...

What analysts pressed on

Analysts expressed concerns about the potential disruption from the Horizon initiative, particularly regarding talent loss and customer continuity. Questions were also raised about the impact of the Bristol Myers Squibb partnership and the expected milestone payments in 2026.

Main topics on the call

• Strategic Transformation — Evotec introduced the Horizon initiative, aiming to streamline operations and enhance commercial execution. This includes reducing sites from 14 to 10 and cutting approximately 800 positions to achieve EUR 75 million in ...
• Just-Evotec Biologics Performance — The segment saw a 104.2% revenue increase in Q4 2025, driven by a strategic agreement with Sandoz valued at $650 million. This pivot from manufacturing to a technology-focused model is expected to drive long-term growth.
• Partnerships and Milestones — Evotec's collaborations with Bristol Myers Squibb and Bayer have advanced, with multiple assets entering clinical trials. Milestone payments totaled $40 million in 2025, with expectations for continued progress in 2026.
• Financial Performance — Q4 2025 revenues grew by 14.5% to EUR 253.3 million, but full-year revenues declined by 1.1% due to challenges in the drug discovery market. Adjusted EBITDA increased significantly, reflecting operational improvements.

Read the full Evotec SE transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 52 Evotec SE earnings call transcripts on record, spanning January 16, 2020 to July 14, 2026. Based on this history, Evotec SE reports quarterly. The most recent call on file is dated July 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

EVT

Exchange

XTRA

Country

DE

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

52

First call

January 16, 2020

Most recent

July 14, 2026

Reporting cadence

quarterly